Drug discovery and development partnership announced between Apollo Therapeutics and Oxford University
Natalia Elliot | July 31, 2024 | News story | Clinical Research, Medical Communications, Research and Development | Apollo Therapeutics, Internal Medicine, Microbiology, drug development, drug discovery, research
Portfolio therapeutics company Apollo Therapeutics has announced earlier this week that it will provide capital and expertise to Oxford University’s biomedical research departments.
Oxford University’s research department will now have access to Apollo’s therapeutic expertise in addition to their programme funding. Both companies aim to provide more support toward early drug development research programmes. Specific areas in which new medicines may be developed include oncology, inflammatory and immunological disorders.
Dr Richard Mason, chief executive officer of Apollo Therapeutics, said: “At Apollo Therapeutics we are ambitious in our mission to translate important new research discoveries into valuable new drugs. We are now working together with six of the world’s top universities and research centres to transform the standard of care in major commercial markets based on breakthroughs in biology and basic medical research made by scientists at these institutions.”
Dr Mairi Gibbs, chief executive officer of Oxford University Innovation, further commented : “We’re keen to provide our academic researchers with multiple avenues to realise the full potential of their cutting-edge research as quickly as possible. If we boost the funding and expertise provided to very early phase drug development programmes this will hasten their progress towards becoming medicines with the potential to licence to industry or become spinout companies. With the support of the research commercialisation team at Oxford University Innovation and our investment partners, we want to speed up the development of more life-saving medicines to help patients most in need.”
Natalia Elliot
31/7/24
Related Content
Custom Pharmaceuticals launches new company for drug product development
Customs Pharmaceuticals, a full-service contract development and manufacturing organisation (CDMO), has launched Centrix Pharma Solutions, …
BioMed X and Novo Nordisk partner on oral peptide drug delivery innovation
BioMed X has announced a new collaboration with Novo Nordisk to improve oral delivery of …
BioDuro and Silicogenix collaborate to advance non-traditional drug development
BioDuro, a contract research, development and manufacturing organisation, has announced a strategic partnership with small …
